AIRLINK 196.20 Increased By ▲ 4.36 (2.27%)
BOP 10.16 Increased By ▲ 0.29 (2.94%)
CNERGY 7.92 Increased By ▲ 0.25 (3.26%)
FCCL 38.30 Increased By ▲ 0.44 (1.16%)
FFL 15.90 Increased By ▲ 0.14 (0.89%)
FLYNG 25.44 Increased By ▲ 0.13 (0.51%)
HUBC 130.65 Increased By ▲ 0.48 (0.37%)
HUMNL 13.79 Increased By ▲ 0.20 (1.47%)
KEL 4.66 Decreased By ▼ -0.01 (-0.21%)
KOSM 6.38 Increased By ▲ 0.17 (2.74%)
MLCF 44.95 Increased By ▲ 0.66 (1.49%)
OGDC 209.79 Increased By ▲ 2.92 (1.41%)
PACE 6.68 Increased By ▲ 0.12 (1.83%)
PAEL 41.05 Increased By ▲ 0.50 (1.23%)
PIAHCLA 17.75 Increased By ▲ 0.16 (0.91%)
PIBTL 8.13 Increased By ▲ 0.06 (0.74%)
POWER 9.38 Increased By ▲ 0.14 (1.52%)
PPL 180.99 Increased By ▲ 2.43 (1.36%)
PRL 40.00 Increased By ▲ 0.92 (2.35%)
PTC 24.41 Increased By ▲ 0.27 (1.12%)
SEARL 111.75 Increased By ▲ 3.90 (3.62%)
SILK 0.99 Increased By ▲ 0.02 (2.06%)
SSGC 38.17 Decreased By ▼ -0.94 (-2.4%)
SYM 19.22 Increased By ▲ 0.10 (0.52%)
TELE 8.75 Increased By ▲ 0.15 (1.74%)
TPLP 12.10 Decreased By ▼ -0.27 (-2.18%)
TRG 66.00 Decreased By ▼ -0.01 (-0.02%)
WAVESAPP 12.29 Decreased By ▼ -0.49 (-3.83%)
WTL 1.69 Decreased By ▼ -0.01 (-0.59%)
YOUW 3.99 Increased By ▲ 0.04 (1.01%)
BR100 12,090 Increased By 159.6 (1.34%)
BR30 35,982 Increased By 322.6 (0.9%)
KSE100 114,866 Increased By 1659.2 (1.47%)
KSE30 36,099 Increased By 534 (1.5%)
World

South Korea in talks with mRNA vaccine makers to make up to 1b doses

  • South Korea already has deals to locally produce three coronavirus vaccines developed by AstraZeneca/Oxford University
Published July 5, 2021

SEOUL: South Korea is in talks with mRNA vaccine makers including Pfizer and Moderna to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately, a senior government official said.

The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia which lags North America and Europe in vaccine rollouts, and put South Korea a step closer to its ambition to become a major vaccine manufacturing centre.

South Korea already has deals to locally produce three coronavirus vaccines developed by AstraZeneca/Oxford University, Novavax, and Russia. It also has a vaccine bottling and packaging deal with Moderna.

"We've been holding frequent talks with big pharmaceutical companies to produce mRNA vaccines," Lee Kang-ho, director general for the global vaccine hub committee under South Korea's health ministry, told Reuters in an interview.

"There are only a few mRNA vaccine developers - Pfizer, Moderna, CureVac and BioNTech. Thus there's a limit to how much they can produce to meet global demand... South Korea is keen to help by offering its facilities and skilled human resources," Lee said.

It's not immediately clear how advanced these talks are and whether and when a deal will be agreed.

BioNTech declined to comment, Moderna and CureVac did not reply to Reuters' requests for comments.

A Pfizer spokesperson said the company is making efforts to enhance its COVID-19 vaccine supply chain but added "we do not have anything specific to announce at this time."

Lee declined to name local vaccine makers which have the capacity to produce mRNA vaccines immediately, but a government source said they include Hanmi Pharmaceuticals Co Ltd and Quratis Co Ltd.

Hanmi confirmed that it has a big capacity reserved for Sanofi's diabetes drug and it can be used for COVID-19 vaccine production as the Sanofi project has stalled.

Quratis, which makes a tuberculosis vaccine, said its new factory built last year can now be used for mRNA vaccine production.

Comments

Comments are closed.